

2016-08-16

Synthesis of aza-rocaglates via ESIPT-mediated (3+2) photocycloaddition

Wenyu Wang, Regina Cencic, Luke Whitesell, Jerry Pelletier, John A Porco. 2016. "Synthesis of Aza-Rocaglates via ESIPT-Mediated (3+2) Photocycloaddition.." Chemistry, Volume 22, Issue 34, pp. 12006 - 12010.

<https://hdl.handle.net/2144/26487>

Downloaded from DSpace Repository, DSpace Institution's institutional repository



Published in final edited form as:

Chemistry. 2016 August 16; 22(34): 12006–12010. doi:10.1002/chem.201602953.

Synthesis of *Aza-Rocaglates* via ESIPT-Mediated (3+2) Photocycloaddition

Wenyu Wang,

Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215, United States

Dr. Regina Cencic,

McGill University, Department of Biochemistry and The Rosalind and Morris Goodman Cancer Research Centre Room 810, 3655 Drummond St., Montreal, QC, H3G 1Y6 (Canada)

Dr. L. Luke Whitesell,

Whitehead Institute for Biomedical Research (WIBR), Cambridge, Massachusetts 02142, United States

Prof. Dr. Jerry Pelletier, and

McGill University, Department of Biochemistry and The Rosalind and Morris Goodman Cancer Research Centre Room 810, 3655 Drummond St., Montreal, QC, H3G 1Y6 (Canada)

Prof. Dr. John A. Porco Jr.

Department of Chemistry, Center for Molecular Discovery (BU-CMD), Boston University, 590 Commonwealth Avenue, Boston, Massachusetts 02215, United States

Abstract

Synthesis of *aza-rocaglates*, nitrogen-containing analogues of the rocaglate natural products, is reported. The route features ESIPT-mediated (3+2) photocycloaddition of 1-alkyl-2-aryl-3-hydroxyquinolinones with the dipolarophile methyl cinnamate. A continuous photoflow reactor was utilized for photocycloadditions. An array of compounds bearing the hexahydrocyclopenta[b]indole core structure was synthesized and evaluated in translation inhibition assays.

Graphical abstract



Aza-rocaglates were prepared from 3-hydroxyquinolinones and methyl cinnamate using ESIPT (3+2) photocycloaddition in a continuous photoflow reactor. A collection of compounds

Correspondence to: John A. Porco, Jr.

Supporting information for this article is given via a link at the end of the document.

containing hexahydrocyclopenta[*b*]indole core was synthesized using this method and evaluated in translation inhibition assays.

Keywords

Rocaglate; Photocycloaddition; ESIPT; Flow Chemistry; Heterocycle

Flavaglines are a family of natural products isolated from plants of the genus *Aglaia* which feature the cyclopenta[*b*]-benzofuran core structure.^[1] After the first isolation of rocaglamide (**1**, Figure 1) by King and coworkers in 1982,^[2] more than 100 natural flavaglines (rocaglates) have been isolated, characterized, and tested for insecticidal, anti-inflammatory, and anticancer activities.^[3] Due to their intriguing structural complexity and biological activities, a number of synthetic chemists have undertaken syntheses of natural flavaglines as well as targeted derivatives with improved or novel biological properties.^[4]

However, with the exception of the carbocyclic analogue **4** for which biological data was not reported,^[5] such studies have been limited to variations of the cyclopenta[*b*]benzofuran core.^[4] Previously, we reported a biomimetic approach towards rocaglates using excited state intramolecular proton transfer (ESIPT)-mediated (3+2) photocycloaddition of 3-hydroxyflavones and dipolarophiles.^[6] Later, we successfully extended the methodology to employ 1,2-dimethyl-3-hydroxyquinolinone (DMQ, **6**) to access various cycloadducts.^[7] For example, photocycloaddition of DMQ (**6**) with methyl cinnamate **7** provided bridged ketone cycloadduct **8** (Scheme 1).

In the current study, we considered syntheses of nitrogen-containing rocaglate analogues employing ESIPT photocycloaddition of 2-aryl-3-hydroxyquinolinones such as **9** wherein it was thought that π - π stacking interactions between the 2-aryl substituent of substrate **9** and the phenyl group of methyl cinnamate **7** may favor the desired cycloaddition geometry (Scheme 2). *Aza*-aglaine cycloadduct **10** may further undergo α -ketol (acyloin) rearrangement to **11** which may be followed by diastereoselective reduction to access *aza*-rocaglates such as **5** bearing the hexahydrocyclopenta[*b*]-indole scaffold. Herein, we outline synthetic and mechanistic studies regarding the *aza*-rocaglates as well as translation inhibition studies of the natural product variants.

We first performed pilot studies with 2-aryl-3-hydroxyquinolinone substrate **12**.^[8b] Under photoirradiation of **12** with dipolarophile **7** ($\lambda > 330$ nm), we did not observe satisfactory conversion to the corresponding cycloadduct **13** (Scheme 3). As our previous studies were performed using a *N*-methyl-3-hydroxyquinolinone substrate (*cf.* Scheme 1), 1-methyl-2-aryl-3-hydroxyquinolinone (*N*-Me-3-HQ, **15**) was chosen as a modified substrate for ESIPT photocycloaddition. The synthesis of derivatives related to **15** has been previously reported.^[8] However, using substrate **14** and polyphosphoric acid (PPA) as solvent,^[8b] a lengthy workup and purification was required and only 34% of the desired product **15** was observed. In order to obtain practical amounts of **15**, development of a new method for the synthesis of *N*-alkyl-3-hydroxyquinolinones was required. After evaluation of reaction conditions, we found that treatment of phenacyl anthranilate **14** with NaH (1.0 equiv.) in

THF led to the production of **15** in 83% yield (Scheme 4A). A proposed mechanism (Scheme 4B) may proceed through formation of hemiaminal **14a** followed by rearrangement to alkoxide **14b**. 3,1-Benzoxazin-4-ones related to **14b** have previously been reported from treatment of phenacyl anthranilates with acetic acid.^[8c] Further reaction of **14b** to iminium **14c** followed by isomerization should generate the intramolecular hydrogen bond-stabilized enolate **14d** (Scheme 4C).^[9] A DFT model of **14d** (Scheme 4C) shows a well-defined arrangement for further transformations.^[10] Cyclization of **14d** to benzoxazepine **14e** followed by rearrangement to zwitterion **14f**, elimination, and acidic workup provides 3-hydroxyquinolinone **15**. Similar benzoxazepine structures have been reported previously in the literature by treatment of phenacyl anthranilates with phosphoryl chloride.^[11] To the best of our knowledge, the synthesis of 1-alkyl-3-hydroxyquinolinones from phenacyl anthranilates under basic conditions has not been previously described.

When substrate **15** was subjected to photoirradiation ($\lambda > 330$ nm) in the presence of methyl cinnamate, cycloadducts were indeed generated. After condition optimization, we found that using trifluorotoluene and trifluoroethanol as co-solvents, *aza*-aglain derivatives **16** and **17** could be isolated in 40% yield (5:1 ratio). However, 48 h was needed to obtain the desired products in which case substantial decomposition was observed. Taking advantage of a recently developed continuous photoflow reactor,^[12] we found that the reaction was complete in 9 h (46% yield, 89% yield b.r.s.m., **16:17** = 5:1). In addition, significantly less decomposition was observed in comparison to batch reactions which facilitated product purification. Reduction of the minor isomer **17** using LiAlH₄ provided an unstable diol which was acylated to afford the *bis-para*-bromobenzoate **18**. The structure and relative stereochemistry of **18** was confirmed using HMBC and NOESY experiments.^[10] Using sodium methoxide-mediated α -ketol rearrangement, followed by diastereoselective reduction, *aza*-rocaglate **20** could be obtained in 77% yield (2 steps) from cycloadduct **16**. The structure of **20** was unambiguously confirmed by X-ray crystal structure analysis of the derived bromobenzoate **21** (Figure 2).^[13] Interestingly, inspection of the X-ray structure reveals that the *N*-methyl moiety is coplanar to the adjacent aryl group indicating a non-pyramidalized nitrogen.^[14] This is likely due to steric interaction of *N*-methyl moiety with the two nearby aryl substituents which appears to prevent nitrogen pyramidalization.

In order to provide a plausible explanation for the differential reactivity of 3-hydroxyquinolinones **12** and **15**, we measured their UV-Vis absorption spectra.^[15] We found that in CH₂Cl₂:MeOH (2:1), both substrates possess an absorption band at approximately 370 nm which can be attributed to charge transfer excitation. More interestingly, we observed an additional absorption (310 nm) for substrate **12** (Figure 3). Therefore, we hypothesized that in solution, **12** may also be represented by an aromatic, dihydroxyquinoline tautomeric form which may diminish its photoreactivity.^[16] In order to support this assertion, we synthesized 3,4-dimethoxyquinoline **22** by treatment of **12** with TMS diazomethane (Scheme 6) for evaluation of its UV absorption properties.^[17] An absorption shoulder at 320 nm was also observed for compound **22** which provides information on the existence of tautomeric form **12a** in solution.

We next targeted the synthesis of more highly functionalized *aza*-rocaglates. Starting with *N*-Me-Br-3-HQ **23** as substrate, obtained from commercially available materials in four steps,^[10] photocycloaddition with methyl cinnamate **7** in the continuous flow reactor led to the production of cycloadduct **24** in 43% yield and excellent selectivity.^[18] Ketol rearrangement, followed by diastereoselective reduction, provided *aza*-rocaglate **26** in good yield. (Scheme 7) Compound **26** was then further transformed to the corresponding hydroxamate **27**^[19] by saponification and coupling.

As part of our study, we also targeted the synthesis of the *N*-H-containing *aza*-rocaglate **5**. After an evaluation of nitrogen protecting groups for synthesis of 3-hydroxyquinolinone substrates, only alkyl protecting groups on the nitrogen could enable access to photocycloadducts (*cf.* Scheme 4). Therefore, an allyl protecting group was chosen to synthesize *N*-allyl-3-HQ **28** using the previously described method. Upon photoirradiation of substrate **28** in the continuous photoflow reactor, cycloadduct **29** could be obtained from *N*-allyl-3-HQ **28** in 43% yield (Scheme 8). Ketol rearrangement of **29** led to the production of **30** which was subjected to hydroxyl-directed reduction to afford *N*-allyl-*aza*-rocaglate **31**. After a thorough evaluation of the allyl deprotection conditions, we found that using Pd (0) / 1,4-*bis*(diphenylphosphino)-butane complex and Meldrum's acid as nucleophile and proton source,^[20] *N*-H-*aza*-rocaglate **5** could be obtained in 45% yield. Other *N*-deallylation conditions reported in the literature failed to provide the desired product.^[21] In order to demonstrate the possibility for further functionalization of the *N*-allyl moiety, **31** was converted into acrylate **32** using olefin cross metathesis.^[22]

Rocaglates have been shown to behave as potent inhibitors of translation by interfering with the activity of eukaryotic initiation factor (eIF) 4A, an RNA helicase necessary for cap-dependent protein synthesis.^[23] We therefore assessed the biological activities of compounds **5**, **26**, **27**, **31**, and **32** *in vitro* in a translation assay programmed with the bicistronic mRNA, FF/HCV/Ren (Figure 4A). In this system firefly luciferase (FF) production is eIF4A-dependent whereas Renilla luciferase (Ren) is not.^[24] Silvestrol (*not shown*) and rocaglates **CR-1-31B**^[19a] and **SDS-1-021(-)**^[3e] potently inhibited FF production (5–10 fold) at 5 μ M. The only *aza*-rocaglate to affect FF production was the *N*-methyl derivative **26**, showing a ~30% reduction in FF production at 20 μ M (Figure 4A). To assess activity towards cellular protein synthesis, HeLa cells were incubated with silvestrol, **CR-1-31B**, or **26** for 1 h and metabolic protein synthesis quantitated (Figure 4B). Whereas 100 nM silvestrol or **CR-1-31B** completely blocked protein synthesis, compound **26** showed modest activity at only at 50 μ M (~20% inhibition).

Consistent with these findings, we also found no evidence for translation inhibition over a 24 h period at concentrations up to 10 μ M using a whole cell assay based on constitutive expression of the rapidly turned-over reporter protein firefly luciferase (Figure 5A). Likewise the compounds had minimal cytotoxic activity in a standard 3-day growth assay over the same concentration range (Figure 5B). Together, these results indicate that *aza*-rocaglates do not possess the same inhibitory potency towards protein synthesis in comparison to related rocaglates such as RHT.^[19c]

In summary, we have employed ESIPT photocycloaddition methodology to synthesize *aza*-rocaglates. Our studies have uncovered differential photocycloaddition reactivities between *N*-H- and *N*-Me-substituted 2-aryl-3-hydroxyquinolinone substrates. A novel method to access 1-alkyl-2-aryl-3-hydroxyquinolinones was also developed for (3+2) photocycloaddition. Use of a continuous photoflow reactor facilitated synthesis of *aza*-rocaglates with both *N*-alkyl and *N*-H substitution. Initial protein synthesis and translation inhibition data indicates that *aza*-rocaglates do not possess activity in comparison to related rocaglates which provides further information on the SAR of the natural product scaffold.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health (GM-073855 to J.A.P, Jr. and R01CA175744 to L.W. and J.A.P, Jr.) and the Canadian Institutes for Health Research (MOP-115126 to J.P.) for research support. We thank Dr. Vincent Eschenbrenner-Lux for computational models, Prof. Aaron Beeler (BU) for helpful discussions, and Dr. Jeffrey Bacon (Boston University) and Matthew Benning (Bruker AXS) for X-ray crystal structure analysis. NMR (CHE-0619339) and MS (CHE-0443618) facilities at Boston University are supported by the NSF. Work at the BU-CMD is supported by R24GM111625.

References

1. Ko FN, Wu TS, Liou MJ, Huang TF, Teng CM. Eur J Pharmacol. 1992; 218:129. [PubMed: 1327822]
2. King ML, Chiang C, Ling H, Fujita E, Ochiai M, Andrew MT. J Chem Soc, Chem Commun. 1982; 20:1150.
3. For recent reports on the chemistry and biology of flavaglines: Basmadjian C, Thuaud F, Ribeiro N, Désaubry L. Future Med Chem. 2013; 5:2185. [PubMed: 24261894] Ribeiro N, Thuaud F, Nebigil C, Désaubry L. Bioorg Med Chem. 2012; 20:1857. [PubMed: 22071525] Ebada SS, Lajkiewicz NJ, Porco JA Jr, Li-Weber M, Proksch P. Prog Chem Org Nat Prod. 2011; 94:1. [PubMed: 21833837] Pan L, Woodard JL, Lucas DM, Fuchs JR, Kinghorn AD. Nat Prod Rep. 2014; 31:924. [PubMed: 24788392] Chu J, Cencic R, Wang W, Porco JA Jr, Pelletier J. Mol Cancer Ther. 2016; 15:136. [PubMed: 26586722] Liu S, Wang W, Brown LE, Qiu C, Lajkiewicz NJ, Zhao T, Zhou J, Porco JA Jr, Wang TT. EBioMedicine. 2015; 11:1600.
4. For recent studies on the synthesis of flavaglines, see: Thuaud F, Ribeiro N, Gaiddon C, Cresteil T, Désaubry L. J Med Chem. 2011; 54:411. [PubMed: 21142180] Hawkins BC, Lindqvist LM, Nhu D, Sharp PP, Segal D, Powell AK, Campbell M, Ryan E, Chambers JM, White JM, Rizzacasa MA, Lessene G, Huang DCS, Burns CJ. Chem Med Chem. 2014; 9:1556. [PubMed: 24677741] Liu T, Nair SJ, Lescarbeau A, Belani J, Peluso S, Conley J, Tilloston B, O'Hearn P, Smith S, Slocum K, West K, Helble J, Douglas M, Bahadoor A, Ali J, McGovern K, Fritz C, Palombella VJ, Wylie A, Castro AC, Tremblay MR. J Med Chem. 2012; 55:8859. [PubMed: 23025805] Lajkiewicz NJ, Cognetta AB III, Niphakis MJ, Cravatt BF, Porco JA Jr. J Am Chem Soc. 2014; 136:2659. [PubMed: 24447064]
5. Bruce I, Cooke NG, Diorazio LJ, Hall RG, Irving E. Tetrahedron Lett. 1999; 40:4279.
6. a) Gerard B, Sangji S, O'Leary D, Porco JA Jr. J Am Chem Soc. 2006; 128:7754. [PubMed: 16771486] b) Gerard B, Cencic R, Pelletier J, Porco JA Jr. Angew Chem. 2007; 119:7977. Angew Chem, Int Ed. 2007; 46:7831. c) Roche SP, Cencic R, Pelletier J, Porco JA Jr. Angew Chem. 2010; 122:6683. Angew Chem, Int Ed. 2010; 49:6533. d) Lajkiewicz NJ, Roche SP, Gerard B, Porco JA Jr. J Am Chem Soc. 2012; 134:13108. [PubMed: 22804454]
7. Xia B, Gerard B, Solano DM, Wan J, Jones G II, Porco JA Jr. Org Lett. 2011; 13:1346. [PubMed: 21338078]

8. For previous syntheses of 3-hydroxyquinolinones, see: Yushchenko DA, Bilokin MD, Duportail G, Mély Y, Pivovarenko VG. *Tetrahedron Lett.* 2006; 47:905. Hradil P, Hlavác J, Lemr K. *J Heterocyclic Chem.* 1999; 36:141. Hradil P, Grepl M, Hlavác J, Lycka A. *Heterocycles.* 2007; 71:269. Hradil P, Kvapil L, Hlavác J, Weidlich T, Lycka A, Lemr K. *J Heterocyclic Chem.* 2000; 37:831.
9. Zhu Y, Drueckhammer DG. *J Org Chem.* 2005; 70:7755. [PubMed: 16149809]
10. Please see the Supporting Information for details.
11. Gandhi SS, Bell KL, Gibson MS. *Tetrahedron.* 1995; 51:13301.
12. For recent reviews on flow photochemistry, see: McQuade DT, Seeberger PH. *J Org Chem.* 2013; 78:6384. [PubMed: 23750988] Su Y, Straathof NJW, Hessel V, Noël T. *Chem Eur J.* 2014; 20:10562. [PubMed: 25056280] Cambié D, Bottecchia C, Straathof NJW, Hessel V, Noël T. *Chem Rev.* 2016; doi: 10.1021/acs.chem-rev.5b00707
13. CCDC 1457719 (**21**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre *via* www.ccdc.cam.ac.uk/data_request/cif.
14. For the X-ray structure of a *N*-methyl indoline with a typical pyrimidalized nitrogen, see: Chiaroni PA, Riche NLC. *Acta Cryst.* 1977; B33:3410.
15. For photophysical studies of 3-hydroxyquinolinones, see: Yushchenko DA, Shvadchak VV, Mély Y, Pivovarenko VG. *New J Chem.* 2006; 30:774. Yushchenko DA, Shvadchak VV, Klymchenko AS, Mély Y. *J Phys Chem A.* 2007; 111:8986. [PubMed: 17718453]
16. Venturella P, Bellino A, Piozzi F, Marino ML. *Heterocycles.* 1976; 4:1089.
17. Spence TWM, Tennant G. *J Chem Soc C.* 1971:3712.
18. The relative stereochemistry of cycloadduct **24** was confirmed by reduction with NaBH₄ to provide an alcohol derivative which was subjected to NOESY NMR studies. See Supporting Information for further details.
19. For the synthesis of rocaglate analogues and biological studies, see: Rodrigo CM, Cencic R, Roche SP, Pelletier J, Porco JA Jr. *J Med Chem.* 2012; 55:558. [PubMed: 22128783] Wolfe AL, Singh K, Zhong Y, Drewe P, Rajsekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Rättsch G, Wendel HG. *Nature.* 2014; 513:65. [PubMed: 25079319] Stone SD, Lajkiewicz NJ, Whitesell L, Hilmy A, Porco JA Jr. *J Am Chem Soc.* 2015; 137:525. [PubMed: 25514979]
20. a) Garro-Helion F, Merzouk A, Guibé F. *J Org Chem.* 1993; 58:6109. b) Wang H, Reisman SE. *Angew Chem.* 2014; 126:6320. *Angew Chem, Int Ed.* 2014; 53:6206.
21. For *N*-deallylation methods, see: Alcaide B, Almendros P, Alonso JM, Aly MF. *Org Lett.* 2001; 3:3781. [PubMed: 11700137] Escoubet S, Gastaldi S, Timokhin V, Bertrand M, Siri D. *J Am Chem Soc.* 2004; 126:12343. [PubMed: 15453768] Kitov PI, Bundle DR. *Org Lett.* 2001; 3:2835. [PubMed: 11529769] Chandrasekhar S, Reddy R, Rao RJ. *Tetrahedron.* 2001; 57:3435.
22. Hutait S, Batra S. *Tetrahedron Lett.* 2010; 51:5781.
23. Novac O, Guenier A, Pelletier J. *Nucl Acids Res.* 2004; 32:902. [PubMed: 14769948]
24. Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. *Nat Rev Drug Discov.* 2015; 14:261. [PubMed: 25743081]




Figure 1.
Rocaglate and Related Natural Products, a Carbocyclic Analogue, and *Aza-Rocaglate* Structures.




Figure 2.
Synthesis and X-ray Crystal Structure of *Aza-Rocaglate 21*.




Figure 3.
UV Absorption Spectra of 3-Hydroxyquinolinones **12** and **15** in Comparison to Dimethoxyquinoline **22**.




Figure 4.
A. Effect of *aza-rocaglates* on *in vitro* translation of FF/HCV/Ren. **B.** Assessing translation inhibition activity of **26** on HeLa cells.







Figure 5. **A.** Translation inhibition (10 μ M) in whole cells based on constitutive expression of firefly luciferase. **B.** 3-day growth assay (Human 293T cancer cells) over the same concentration.

**Scheme 1.**


Previous Studies on Photocycloadditions Using 3-Hydroxyquinolinones (3-HQ's).




Scheme 2.
Planned Synthesis of *Aza-Rocaglates*.




Scheme 3.
Attempted (3+2) Photocycloaddition of **12**.

**Scheme 4.**


A Synthesis of *N*-Me-3-HQ **15**; B. Proposed Mechanism; C. DFT Model of Intermediate **14d** (B3LYP_6-31G**++).




Scheme 5.
 (3+2) Photocycloaddition and Prototype Synthesis of an *Aza-Rocaglate*.



Scheme 6.
Methylation of an *N*-H-3-hydroxyquinolinone.



Scheme 7.
Synthesis of an Advanced *N*-methyl-*aza*-rocaglate **27**.



Scheme 8.
Synthesis of *N*-H-aza-rocaglate **5**.